

RECEIVED
NOV 1 8 2002
TC 1700

RECEIVED

NOV PATER POOZ #1 6

TECH CENTER 1600/2900

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Waskington, DC 20231.

November 12, 2002

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Guy Krippner et al.

RECEIVED

Application No.

10/088,282

NOV 2 1 2002

Filed

For

March 15, 2002

TECH CENTER 1600/2900

Docket No.

150070.402USPC

Date

ANTIVIRAL AGENTS

November 12, 2002

Commissioner for Patents Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Guy Krippner et al.

Seed Intellectual Property Law Group PLLC

Karl R. Hermanns Registration No. 33,507

Enclosures:

Postcard Form PTO/SB/21 Forms PTO-1449 Cited References (7)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

D:\NrPortbl\iManage\JASONA\334201_1.DOC

APPLICATION NO ECEIVED
10/088,282

NOV 1 8 2002

GROUP ART UNIT TC 1700 ATTY, DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 150070.402USPC CHADEN APPLICANT INFORMATION DISCLOSURE STATEMENT Guy Krippner et al. (Use several sheets if necessary) FILING DATE March 15, 2002 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME **CLASS SUBCLASS** INITIAL IF APPROPRIATE AARECEIVED AB NOV 2 1 2002 AC AD TECH CENTER 1600/2900 ΑE PRECEIVE PHOOLSON FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE COUNTRY NUMBER YES NO WO 99/64036 12/16/99 **WIPO** AF X WO 00/55149 09/21/00 **WIPO** AG X ΑH ΑI OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Matrosovich, M.N., "Towards the Development of Antimicrobial Drugs Acting by Inhibition of Pathogen Attachment to Host Cells: A Need for Polyvalency," Fed. of ΑJ European Biochem. Soc., 252(1,2):1-4, 1989. Spaltenstein, A. et al., "Polyacrylamides Bearing Pendant a-Sialoside Groups Strongly Inhibit a Agglutination of Erythrocytes by Influenza Virus," J. Am. Chem. Soc., Vol. 113, ΑK pp. 686-687, 1991. Glick, G. et al., "Ligand Recognition by Influenza Virus. The Binding of Bivalent ALSialosides," J. of Bio. Chem., 266(35):23660-23669, December 15, 1991. Kramer, R. et al., "Spanning Binding Sites on Allosteric Proteins with Polymer-Linked AM Ligand Dimers," Nature, Vol. 395, pp. 710-713, October 15, 1998. Mammen, M. et al.,"Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors," Angew. Chem. Int'l Ed., Vol. 37, pp. 2754-AN

EXAMINER DATE CONSIDERED

AO

2794, 1998.

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).